Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 combinations in biliary tract cancer
NCT03267940Phase 1Terminated
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of pegvorhyaluronidase alfa in cholangiocarcinoma (CCA) and gallbladder adenocarcinoma (6 arms), sponsored by Halozyme Therapeutics, Inc. Primary endpoints: Number of Participants With Adverse Events up to 508 days, Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters up to 508 days and 3 more. Started Oct 2017; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
cholangiocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT03267940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267940.